This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Medesis Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jean-Claude Maurel
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
no data
CEO ownership
4.7%
Management average tenure
no data
Board average tenure
6.7yrs
Recent management updates
Recent updates
CEO
Jean-Claude Maurel
no data
Tenure
Dr. Jean-Claude Maurel, M.D., MHB serves as Chief Executive officer, President and Member of Management Board at Medesis Pharma SA and also serves as its Chairman of the Management Board. Dr. Maurel has wo...
Board Members
Name
Position
Tenure
Compensation
Ownership
Gerald Batist
Member of International Scientific Advisory Board - Oncology
no data
no data
no data
Guy Rouleau
Member of International Scientific Advisory Board - Neuro-Psychiatry
no data
no data
no data
Serge Gauthier
Member of International Scientific Advisory Board - Neuro-Psychiatry
no data
no data
no data
Claudio Cuello
Member of International Scientific Advisory Board - Neuro-Psychiatry
no data
no data
no data
Paul Loubet
Member of International Scientific Advisory Board - Infectious diseases
no data
no data
no data
Sylvie Mader
Member of International Scientific Advisory Board - Oncology
no data
no data
no data
Jacques Touchon
Member of International Scientific Advisory Board - Neuro-Psychiatry
no data
no data
no data
Olivier Connes
Chairman of the Supervisory Board
6.7yrs
no data
no data
Bernard Connes
Member of the Supervisory Board
5.9yrs
no data
no data
Cedric Navas
Member of the Supervisory Board
6.7yrs
no data
no data
Jean-Philippe Causse
Member of the Supervisory Board
3.9yrs
no data
1.74% € 30.9k
Jean-Marie Cazaledes
Member of the Supervisory Board
9.9yrs
no data
3.5% € 62.0k
6.7yrs
Average Tenure
Experienced Board: 76D's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2025/05/15 16:03
End of Day Share Price
2025/03/11 00:00
Earnings
2024/06/30
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medesis Pharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.